C
Compass Therapeutics D
D
CMPX
2.03000
USD
-0.10
(-4.47%)
Post Trading·2.02000USD-0.01000(-0.49%)
Volume
154,617
EPS
-0
Div Yield
-
P/E
-5
Market Cap
365,578,467
Title: Compass Therapeutics
Sector: Healthcare
Industry: Biotechnology
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.